Limit search to available items
Book Cover
E-book
Author Hurvitz, Sara

Title HER2-Positive Breast Cancer
Published Philadelphia : Elsevier, 2018
Online access available from:
ScienceDirect eBooks    View Resource Record  

Copies

Description 1 online resource (265 pages)
Contents Front Cover; HER2-Positive Breast Cancer; HER2-Positive Breast Cancer; Copyright; Dedication; List of Contributors; Preface; Acknowledgements; Contents; I -- BACKGROUND/TESTING; 1 -- The Molecular Biology of HER2 and HER2-Targeted Therapies; DISCOVERY OF THE ONCOGENE ERBB; ERBB2/HER2/NEU GENE AMPLIFICATION IN HUMAN BREAST CANCER; HER2 IS A TYROSINE KINASE RECEPTOR; DRUGS TARGETING PATHOLOGIC HER2 SIGNALING; MECHANISMS OF RESISTANCE TO HER2-TARGETED THERAPIES; REFERENCES; 2 -- HER2 Testing in the Era of Changing Guidelines; BACKGROUND
COMPANION DIAGNOSTICS AND US FOOD AND DRUG ADMINISTRATION DIAGNOSTIC CRITERIAINFORM HER2 FISH Assay; HercepTest and Other IHC Companion Diagnostic Assays; PathVysion HER2 FISH Assay; In Situ HER2 Assays Using Bright-Field Microscopy; NGS and Foundation One CDx; 2007 ASCO-CAP GUIDELINES FOR HER2 TESTING; IHC Changes From the FDA-Approved Requirements; FISH Changes From FDA-Approved Requirements; Challenges With the 2007 ASCO-CAP Guidelines; 2013/2014 ASCO-CAP GUIDELINES FOR HER2 TESTING; IHC Testing; ISH Testing; Problems With ISH Testing according to the 2013/2014 Guidelines
LAPATINIB COMBINATIONS IN HER2-POSITIVE METASTATIC BREAST CANCERLapatinib Plus Capecitabine; Lapatinib Plus Trastuzumab; Lapatinib Plus Vinorelbine; TRASTUZUMAB AND CHEMOTHERAPY COMBINATIONS IN HER2-POSITIVE METASTATIC BREAST CANCER; Trastuzumab Plus Vinorelbine; Trastuzumab Plus Capecitabine; Trastuzumab/Pertuzumab Plus Capecitabine; Trastuzumab Plus Gemcitabine; HORMONE RECEPTOR POSITIVE, HER2-POSITIVE METASTATIC BREAST CANCER; CONCLUSIONS; REFERENCES; 5 -- Central Nervous System Metastases in HER2-Positive Breast Cancer; BACKGROUND; DIAGNOSIS; PROGNOSTIC FACTORS; TREATMENT
TRASTUZUMAB BIOSIMILARSENDOCRINE THERAPY WITH HER2 THERAPY; AMERICAN SOCIETY OF CLINICAL ONCOLOGY GUIDELINES; NATIONAL COMPREHENSIVE CANCER NETWORK GUIDELINES; TOXICITIES; ONGOING PHASE III TRIALS IN THE FIRST-LINE SETTING; LIMITATIONS OF CURRENT STUDIES AND FUTURE DIRECTIONS; REFERENCES; 4 -- HER2-Positive Breast Cancer: Second Line and Beyond; INTRODUCTION; CONTINUING HER2-DIRECTED THERAPY BEYOND PROGRESSION ON TRASTUZUMAB; TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER; Trastuzumab Emtansine for Second-Line Therapy; Trastuzumab Emtansine Beyond Second Line
USC/BCIRG-TRIO CENTRAL LABORATORYAssociation of Each ASCO-CAP FISH Group With HER2 Protein Expression Level; Association of Each ASCO-CAP FISH Group With Clinical Outcomes; EXPECTATIONS; CONCLUSION; REFERENCES; II -- ADVANCED DISEASE; 3 -- Optimal First-Line Treatment of Advanced HER2-Positive Breast Cancer; INTRODUCTION; TRASTUZUMAB; THE ADDITION OF TRASTUZUMAB TO CHEMOTHERAPY; THE ADDITION OF OTHER DRUGS TO THE TRASTUZUMAB AND TAXANE BACKBONE; TRASTUZUMAB WITH OTHER CHEMOTHERAPY AGENTS; TRASTUZUMAB AS A SINGLE AGENT; PERTUZUMAB; TRASTUZUMAB EMTANSINE; LAPATINIB; NERATINIB
Summary Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. Includes a timely section on innovative future therapies
Notes SURGICAL RESECTION
Print version record
Subject Breast -- Cancer
Breast -- Cancer.
Form Electronic book
Author McCann, Kelly
ISBN 0323581234
9780323581233